SecBot SecBot
6-K ·Filed Jun 1, 2026

GLAXF

GSK plc
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001654954-26-005584
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine buyback disclosure with no new program authorization or change in pace. Monitor GSK's next quarterly filing for any update on buyback program size or duration. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
GLAXF ▲ +5.44% at T+60d
NEUTRAL call +5.44% · α vs SPY +4.21% · entry $24.25 → $25.57
Entry = T+0 close
Jun 1, 2026
via day close
T+1d
-1.28%
call -1.28% · α -1.42%
$23.94
settled 5mo ago
T+5d
+1.69%
call +1.69% · α +4.44%
$24.66
settled 5mo ago
T+20d
+4.45%
call +4.45% · α +5.75%
$25.33
settled 4mo ago
T+60d
+5.44%
call +5.44% · α +4.21%
$25.57
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc disclosed routine open-market share repurchases totaling 1,248,271 ordinary shares between May 26-29, 2026, as part of its existing buyback program. The purchases were executed through a non-discretionary broker agreement at volume-weighted average prices ranging from 1,899.95 GBp to 1,932.82 GBp per share. This is a standard capital return disclosure with no material new information for traders.

Key Facts

  • GSK purchased 1,248,271 ordinary shares over four trading days (May 26-29, 2026) at VWAPs between 1,899.95 GBp and 1,932.82 GBp.
  • Total shares bought since program start on May 11, 2026: 4,590,420 ordinary shares.
  • Post-purchase, GSK holds 265,968,706 shares in treasury (6.57% of voting rights) and has 4,050,256,108 shares outstanding.
  • Purchases were made under a non-discretionary agreement with Citigroup Global Markets Limited dated May 8, 2026.

Financial Impact

Approximately £23.9 million deployed in the reported week (1,248,271 shares × ~£19.15 average VWAP). Cumulative program spend since May 11: ~£88 million.

share counttreasury sharesvoting rights

Risk Factors

  • Buyback pace may slow if GSK prioritizes other capital allocation (M&A, R&D spend).
  • No change to underlying business fundamentals — share price impact from buybacks is typically modest and gradual.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
41% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005584
Document: 0001654954-26-005584-index-headers.html0001654954-26-005584
Document: 0001654954-26-005584-index.html0001654954-26-005584
Document: 0001654954-26-005584.txt0001654954-26-005584
51 reports for GLAXF
Performance horizon
46% Hit rate @ T+5 6 of 13 directional calls Went positive at some point 7 of 13 best @ T+20▲ +9.49%Jun 9, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
TypeNow
Jun 10, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$25.12 $25.25▲ +0.52%▼ −1.62%$26.12 (+3.98%)
Jun 9, 2026
20w ago
6-K
NEUTRAL ★ 1/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 9, 2026
20w ago
6-K
BULLISH ★ 7/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
May 28, 2026
21w ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.12 (+6.27%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.12 (+2.15%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 22, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.12 (+0.46%)
Showing 10 of 51

US Market Status

Market Closed — Opens Thu (11h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026